8-K: Novo Integrated Sciences Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price

Novo Integrated Sciences, Inc. (NVOS) is set to be delisted from the Nasdaq Stock Market after failing to meet the minimum bid price requirement, with trading continuing on the OTC Market.

Summary

• Novo Integrated Sciences, Inc. (the Company) received notification from Nasdaq regarding its non-compliance with the minimum bid price requirement.
• On November 4, 2024, Nasdaq informed the Company that its common stock would be delisted, and trading would be suspended on November 6, 2024.
• The Company's common stock began trading on the OTC Market under the symbol NVOS on November 6, 2024.
• On April 28, 2025, Nasdaq notified the Company that it would file a Form 25 with the Securities and Exchange Commission to complete the delisting.
• The delisting will become effective 10 days after Nasdaq files Form 25.
• The Company's common stock will continue to be quoted on the OTC Market after the Form 25 filing and effectiveness.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq, which is generally viewed unfavorably by investors. While the company will continue trading on the OTC market, this is not seen as a positive outcome.

Positives

• The company's common stock will continue to be quoted on the OTC Market, providing investors with continued trading access.

Negatives

• The company is being delisted from the Nasdaq due to non-compliance with the minimum bid price requirement.
• The delisting could negatively impact investor confidence and the company's access to capital.

Risks

• Continued trading on the OTC Market may result in lower trading volumes and liquidity.
• The delisting could make it more difficult for the company to raise capital in the future.
• The company's stock price may be negatively impacted by the delisting.

Future Outlook

The company's common stock will continue to be quoted on the OTC Market following the delisting from Nasdaq.

Industry Context

Delisting from major exchanges like Nasdaq can be a significant setback for companies, often leading to decreased investor confidence and potentially impacting their ability to raise capital. Companies facing delisting often explore strategies to regain compliance or seek alternative listing venues.

Comparison to Industry Standards

• Companies like China Xiangtai Food Co., Ltd. and Farmmi, Inc. have faced similar delisting notices from Nasdaq due to low stock prices.
• These companies often try to regain compliance through reverse stock splits or by demonstrating sustained price improvement.
• Compared to companies that successfully regain compliance, Novo Integrated Sciences has not yet demonstrated a clear path to relisting on Nasdaq.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• Employees may experience uncertainty regarding the company's future prospects.
• The company's reputation may be negatively impacted.

Next Steps

• Nasdaq will file Form 25 with the SEC to complete the delisting.
• The delisting will be effective 10 days after the Form 25 is filed.
• The Company's common stock will continue to be quoted on the OTC Market.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, OTC Market, NVOS, Novo Integrated Sciences, Form 25